{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:48:21Z","timestamp":1792000101415,"version":"4.4.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"am","delay-in-days":372,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R35GM151109"],"award-info":[{"award-number":["R35GM151109"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008884","name":"Edward P Evans Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008884","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018896","name":"Sylvester Comprehensive Cancer Center, University of Miami Health Systems","doi-asserted-by":"publisher","award":["P30CA240139"],"award-info":[{"award-number":["P30CA240139"]}],"id":[{"id":"10.13039\/100018896","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","bmn.com","clinicalkey.com","cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.tips.2024.06.006","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T12:12:27Z","timestamp":1721218347000},"page":"691-707","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["BTK inhibitors: past, present, and future"],"prefix":"10.1016","volume":"45","author":[{"given":"Allison","family":"Cool","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Nong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Skye","family":"Montoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4407-6325","authenticated-orcid":false,"given":"Justin","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2024.06.006_bb0005","doi-asserted-by":"crossref","DOI":"10.1111\/sji.12931","article-title":"B cell signalling pathways\u2014new targets for precision medicine in chronic lymphocytic leukaemia","volume":"92","author":"Sk\u00e5nland","year":"2020","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.tips.2024.06.006_bb0010","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2147\/JEP.S265284","article-title":"The role of BTK inhibition in the treatment of chronic lymphocytic leukemia: a clinical view","volume":"13","author":"Tambaro","year":"2021","journal-title":"J. Exp. Pharmacol."},{"key":"10.1016\/j.tips.2024.06.006_bb0015","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.molimm.2004.04.008","article-title":"B cell antigen receptor signaling 101","volume":"41","author":"Dal Porto","year":"2004","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.tips.2024.06.006_bb0020","doi-asserted-by":"crossref","first-page":"860","DOI":"10.3390\/cancers14040860","article-title":"Regulation of B-cell receptor signaling and its therapeutic relevance in aggressive B-cell lymphomas","volume":"14","author":"Profit\u00f3s-Pelej\u00e0","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.tips.2024.06.006_bb0025","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000533610","article-title":"Chronic lymphocytic leukemia: disease biology","volume":"147","author":"Koehrer","year":"2023","journal-title":"Acta Haematol."},{"key":"10.1016\/j.tips.2024.06.006_bb0030","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41375-022-01732-9","article-title":"Managing Waldenstr\u00f6m's macroglobulinemia with BTK inhibitors","volume":"37","author":"Buske","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.tips.2024.06.006_bb0035","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1182\/bloodadvances.2023012221","article-title":"BTK inhibitors in CLL: second-generation drugs and beyond","volume":"8","author":"Tam","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.tips.2024.06.006_bb0040","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s12272-019-01124-1","article-title":"Development of BTK inhibitors for the treatment of B-cell malignancies","volume":"42","author":"Kim","year":"2019","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.tips.2024.06.006_bb0045","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.3390\/molecules28052400","article-title":"Bruton's tyrosine kinase inhibitors (BTKIs): review of preclinical studies and evaluation of clinical trials","volume":"28","author":"Rozkiewicz","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.tips.2024.06.006_bb0050","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.3390\/ijms25063234","article-title":"Targeting BTK in B cell malignancies: from mode of action to resistance mechanisms","volume":"25","author":"Mouhssine","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tips.2024.06.006_bb0055","doi-asserted-by":"crossref","first-page":"10374","DOI":"10.3390\/ijms241210374","article-title":"Treatment refractoriness in chronic lymphocytic leukemia: old and new molecular biomarkers","volume":"24","author":"Maher","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tips.2024.06.006_bb0060","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13045-022-01353-w","article-title":"BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies","volume":"15","author":"Alu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.tips.2024.06.006_bb0065","first-page":"62","article-title":"Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor","volume":"142","author":"Gomez","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.tips.2024.06.006_bb0070","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41408-023-00902-x","article-title":"Zanubrutinib: past, present, and future","volume":"13","author":"Tam","year":"2023","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.tips.2024.06.006_bb0075","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of resistance to noncovalent Bruton\u2019s tyrosine kinase inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2024.06.006_bb0080","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTK","volume":"35","author":"Woyach","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tips.2024.06.006_bb0085","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/bjh.18418","article-title":"Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma","volume":"200","author":"Nakhoda","year":"2023","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.tips.2024.06.006_bb0090","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/ajh.26864","article-title":"Front-line chronic lymphocytic leukemia: the role of chemoimmunotherapy","volume":"98","author":"Kim","year":"2023","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.tips.2024.06.006_bb0095","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41408-021-00467-7","article-title":"Ibrutinib combinations in CLL therapy: scientific rationale and clinical results","volume":"11","author":"Timofeeva","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.tips.2024.06.006_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41571-023-00821-7","article-title":"Complicated regulatory decision-making following inconsistent trial results: the issue with ibrutinib for mantle cell lymphoma","volume":"21","author":"Cliff","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.tips.2024.06.006_bb0105","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2024.06.006_bb0110","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2024.06.006_bb0115","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2024.06.006_bb0120","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2024.06.006_bb0125","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tips.2024.06.006_bb0130","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.668162","article-title":"Acalabrutinib: a selective Bruton tyrosine kinase inhibitor for the treatment of B-cell malignancies","volume":"11","author":"Abbas","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.tips.2024.06.006_bb0135","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s00280-018-3546-3","article-title":"Ibrutinib brain distribution: a preclinical study","volume":"81","author":"Goldwirt","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.tips.2024.06.006_bb0140","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1080\/10428194.2024.2333985","article-title":"Bruton's tyrosine kinase (BTK) inhibitors for the treatment of primary central nervous system lymphoma (PCNSL): current progress and latest advances","volume":"65","author":"Schaff","year":"2024","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.tips.2024.06.006_bb0145","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1111\/bjh.16946","article-title":"Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance\/MD Anderson Cancer Center experience","volume":"192","author":"Lewis","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.tips.2024.06.006_bb0150","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.18.02403","article-title":"Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma","volume":"37","author":"Younes","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tips.2024.06.006_bb0155","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1182\/bloodadvances.2022009389","article-title":"Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial","volume":"7","author":"Johnson","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.tips.2024.06.006_bb0160","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.3390\/cancers11121834","article-title":"Overcoming ibrutinib resistance in chronic lymphocytic leukemia","volume":"11","author":"Pu\u0142a","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.tips.2024.06.006_bb0165","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1182\/blood.2019003715","article-title":"Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib","volume":"136","author":"Sun","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.tips.2024.06.006_bb0170","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2147\/BLCTT.S326627","article-title":"Use of BTK inhibitors in chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): a practical guidance","volume":"12","author":"St-Pierre","year":"2022","journal-title":"Blood Lymphat. Cancer"},{"key":"10.1016\/j.tips.2024.06.006_bb0175","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1038\/s41375-021-01252-y","article-title":"Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies","volume":"35","author":"Furman","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.tips.2024.06.006_bb0180","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2024.06.006_bb0185","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.3324\/haematol.2020.272500","article-title":"Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"106","author":"Rogers","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.tips.2024.06.006_bb0190","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.tips.2024.06.006_bb0195","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2024.06.006_bb0200","doi-asserted-by":"crossref","first-page":"5589","DOI":"10.1182\/bloodadvances.2022008325","article-title":"Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance","volume":"6","author":"Blombery","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.tips.2024.06.006_bb0205","article-title":"Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on- and off-target inhibition","volume":"2020","author":"Liclican","year":"1864","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"10.1016\/j.tips.2024.06.006_bb0210","article-title":"Three-year follow-up analysis of phase 1\/2 study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma","volume":"6","author":"Yonezawa","year":"2024","journal-title":"Neurooncol. Adv."},{"key":"10.1016\/j.tips.2024.06.006_bb0215","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s40164-023-00448-5","article-title":"Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies","volume":"12","author":"Song","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.tips.2024.06.006_bb0220","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1182\/bloodadvances.2022009168","article-title":"Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1\/2, open-label, multicenter, single-arm study","volume":"7","author":"Deng","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.tips.2024.06.006_bb0225","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.omto.2021.03.015","article-title":"Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma","volume":"21","author":"Yu","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.tips.2024.06.006_bb0230","doi-asserted-by":"crossref","first-page":"12110","DOI":"10.1182\/blood-2022-158865","article-title":"A Phase III, randomized, double-blind, placebo-controlled, multi-center study evaluating the efficacy and safety of orelabrutinib plus R-CHOP versus placebo plus R-CHOP in treatment-na\u00efve patients with MCD subtype diffuse large B-cell lymphoma","volume":"140","author":"Xu","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.tips.2024.06.006_bb0235","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1182\/bloodadvances.2022008447","article-title":"Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance","volume":"7","author":"Naeem","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.tips.2024.06.006_bb0240","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.3390\/cancers15143648","article-title":"Non-covalent Bruton\u2019s tyrosine kinase inhibitors in the treatment of chronic lymphocytic leukemia","volume":"15","author":"Montoya","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.tips.2024.06.006_bb0245","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11523-021-00857-8","article-title":"Bruton tyrosine kinase inhibitors in B-cell malignancies: their use and differential features","volume":"17","author":"Shirley","year":"2022","journal-title":"Target. Oncol."},{"key":"10.1016\/j.tips.2024.06.006_bb0250","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2020-134970","article-title":"LOXO-305, a next generation, highly selective, non-covalent BTK inhibitor in previously treated CLL\/SLL: results from the phase 1\/2 BRUIN Study","volume":"136","author":"Mato","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.tips.2024.06.006_bb0255","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2300696","article-title":"Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia","volume":"389","author":"Mato","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2024.06.006_bb0260","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1182\/blood-2023-181090","article-title":"Fixed-duration pirtobrutinib combined with venetoclax \u00b1 rituximab in relapsed\/refractory chronic lymphocytic leukemia: updated results, including MRD data, from the BRUIN phase 1b study","volume":"142","author":"Roeker","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.tips.2024.06.006_bb0265","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.3390\/ijms25042208","article-title":"Bruton's tyrosine kinase inhibitors: recent updates","volume":"25","author":"Fares","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tips.2024.06.006_bb0270","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.2217\/fon-2022-0976","article-title":"BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma","volume":"18","author":"Eyre","year":"2022","journal-title":"Future Oncol."},{"key":"10.1016\/j.tips.2024.06.006_bb0275","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1158\/1078-0432.CCR-23-0409","article-title":"New means and challenges in the targeting of BTK","volume":"30","author":"Nawaratne","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tips.2024.06.006_bb0280","doi-asserted-by":"crossref","first-page":"5698","DOI":"10.1182\/bloodadvances.2022008955","article-title":"Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors","volume":"7","author":"Qi","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.tips.2024.06.006_bb0285","doi-asserted-by":"crossref","DOI":"10.1126\/science.adi5798","article-title":"Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1\/3 degrader NX-2127","volume":"383","author":"Montoya","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.tips.2024.06.006_bb0290","doi-asserted-by":"crossref","first-page":"764","DOI":"10.3390\/jpm11080764","article-title":"Non-covalent BTK inhibitors\u2014the new BTKids on the block for B-cell malignancies","volume":"11","author":"Lewis","year":"2021","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.tips.2024.06.006_bb0295","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1158\/2159-8290.CD-17-1409","article-title":"The BTK inhibitor ARQ 531 targets ibrutinib-resistant CLL and Richter transformation","volume":"8","author":"Reiff","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.tips.2024.06.006_bb0300","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1158\/2159-8290.CD-23-0670","article-title":"First-in-human study of the reversible BTK inhibitor nemtabrutinib in patients with relapsed\/refractory chronic lymphocytic leukemia and B-cell non-Hodgkin lymphoma","volume":"14","author":"Woyach","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.tips.2024.06.006_bb0305","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s13045-022-01386-1","article-title":"Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia","volume":"15","author":"Muhowski","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.tips.2024.06.006_bb0310","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3324\/haematol.2021.279158","article-title":"Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton tyrosine kinase","volume":"107","author":"Aslan","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.tips.2024.06.006_bb0315","doi-asserted-by":"crossref","DOI":"10.1101\/mcs.a006283","article-title":"Leukemic presentation and progressive genomic alterations of MCD\/C5 diffuse large B-cell lymphoma (DLBCL)","volume":"9","author":"Kim","year":"2023","journal-title":"Cold Spring Harb. Mol. Case Stud."},{"key":"10.1016\/j.tips.2024.06.006_bb0320","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3324\/haematol.2021.280061","article-title":"Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies","volume":"107","author":"Allan","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.tips.2024.06.006_bb0325","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1182\/blood.2021011516","article-title":"Evaluation of vecabrutinib as a model for noncovalent BTK\/ITK inhibition for treatment of chronic lymphocytic leukemia","volume":"139","author":"Jebaraj","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.tips.2024.06.006_bb0330","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/leu.2017.32","article-title":"Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia","volume":"31","author":"Deng","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.tips.2024.06.006_bb0335","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40364-022-00357-5","article-title":"Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma","volume":"10","author":"Zhang","year":"2022","journal-title":"Biomark. Res."},{"key":"10.1016\/j.tips.2024.06.006_bb0340","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.591577","article-title":"Genetic and non-genetic mechanisms of resistance to BCR signaling inhibitors in B cell malignancies","volume":"10","author":"Ondrisova","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.tips.2024.06.006_bb0345","doi-asserted-by":"crossref","first-page":"175526","DOI":"10.1016\/j.ejphar.2023.175526","article-title":"Synergistic disruption of BTK and BCL-2 causes apoptosis while inducing ferroptosis in double-hit lymphoma","volume":"943","author":"Setiawan","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.tips.2024.06.006_bb0350","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/s41375-021-01470-4","article-title":"Inhibitors of Bcl-2 and Bruton\u2019s tyrosine kinase synergize to abrogate diffuse large B-cell lymphoma growth in vitro and in orthotopic xenotransplantation models","volume":"36","author":"Bertram","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.tips.2024.06.006_bb0355","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1158\/1078-0432.CCR-17-3761","article-title":"Comprehensive safety analysis of venetoclax monotherapy for patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"24","author":"Davids","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tips.2024.06.006_bb0360","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus Venetoclax for the treatment of mantle-cell lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2024.06.006_bb0365","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/jamaoncol.2021.1649","article-title":"Ibrutinib Plus venetoclax for first-line treatment of chronic lymphocytic leukemia: a nonrandomized phase 2 trial","volume":"7","author":"Jain","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.tips.2024.06.006_bb0370","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood-2020-134446","article-title":"Ibrutinib (Ibr) plus venetoclax (Ven) for first-line treatment of chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL): 1-year disease-free survival (DFS) results from the MRD cohort of the phase 2 CAPTIVATE Study","volume":"136","author":"Wierda","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.tips.2024.06.006_bb0375","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200006","article-title":"Fixed-duration ibrutinib\u2013venetoclax in patients with chronic lymphocytic leukemia and comorbidities","volume":"1","author":"Kater","year":"2022","journal-title":"NEJM Evid."},{"key":"10.1016\/j.tips.2024.06.006_bb0380","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/blood-2023-186432","article-title":"Initial results of a phase 1 dose escalation study of LP-168, a novel covalent and non-covalent next-generation inhibitor of Bruton's tyrosine kinase","volume":"142","author":"Woyach","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.tips.2024.06.006_bb0385","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1182\/blood-2023-178259","article-title":"Targeting covalent and non-covalent Btki-resistant CLL using the dual irreversible\/reversible 4th generation BTK inhibitor LP-168","volume":"142","author":"Gordon","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.tips.2024.06.006_bb0390","doi-asserted-by":"crossref","first-page":"4400","DOI":"10.1182\/blood-2023-180485","article-title":"A Novel dual covalent and non-covalent next generation inhibitor of Bruton's tyrosine kinase LP-168 in patients with relapsed\/refractory B cell non-Hodgkin lymphoma: safety and efficacy results from a phase 1 Study","volume":"142","author":"Song","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.tips.2024.06.006_bb0395","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1182\/blood-2023-180109","article-title":"First results from a phase 1, first-in-human study of the Bruton's tyrosine kinase (BTK) degrader Bgb-16673 in patients (Pts) with relapsed or refractory (R\/R) B-cell malignancies (BGB-16673-101)","volume":"142","author":"Seymour","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.tips.2024.06.006_bb0400","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1182\/blood-2023-179508","article-title":"Initial findings from a first-in-human Phase 1a\/b trial of NX-5948, a selective Bruton's tyrosine kinase (BTK) degrader, in patients with relapsed\/refractory B cell malignancies","volume":"142","author":"Searle","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.tips.2024.06.006_bb0405","doi-asserted-by":"crossref","first-page":"812","DOI":"10.3390\/pharmaceutics15030812","article-title":"Cereblon-recruiting PROTACs: will new drugs have to face old challenges?","volume":"15","author":"Cie\u015blak","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.tips.2024.06.006_bb0410","doi-asserted-by":"crossref","first-page":"E387","DOI":"10.1002\/ajh.27110","article-title":"A matching-adjusted indirect comparison of acalabrutinib versus zanubrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"98","author":"Kittai","year":"2023","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.tips.2024.06.006_bb0415","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41408-024-01044-4","article-title":"Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed\/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison","volume":"14","author":"Shadman","year":"2024","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.tips.2024.06.006_bb0420","doi-asserted-by":"crossref","first-page":"8122","DOI":"10.1021\/acs.jmedchem.4c00220","article-title":"Discovery and preclinical characterization of BIIB129, a covalent, selective, and brain-penetrant BTK inhibitor for the treatment of multiple sclerosis","volume":"67","author":"Himmelbauer","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2024.06.006_bb0425","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.662223","article-title":"Bruton\u2019s tyrosine kinase (BTK) inhibitors and autoimmune diseases: making sense of BTK inhibitor specificity profiles and recent clinical trial successes and failures","volume":"12","author":"Ringheim","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tips.2024.06.006_bb0430","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.3390\/pharmaceutics14051035","article-title":"Development of new drugs for autoimmune hemolytic anemia","volume":"14","author":"Xiao","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.tips.2024.06.006_bb0435","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.clim.2016.01.012","article-title":"Btk inhibition treats TLR7\/IFN driven murine lupus","volume":"164","author":"Bender","year":"2016","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.tips.2024.06.006_bb0440","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2147\/ITT.S288550","article-title":"Bruton's tyrosine kinase inhibition for the treatment of rheumatoid arthritis","volume":"10","author":"Arneson","year":"2021","journal-title":"Immunotargets Ther."},{"key":"10.1016\/j.tips.2024.06.006_bb0445","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/acr2.11511","article-title":"Efficacy and safety of the Bruton's tyrosine kinase inhibitor evobrutinib in systemic lupus erythematosus: results of a phase II, randomized, double-blind, placebo-controlled dose-ranging trial","volume":"5","author":"Wallace","year":"2023","journal-title":"ACR Open Rheumatol."},{"key":"10.1016\/j.tips.2024.06.006_bb0450","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1182\/blood.V128.22.1259.1259","article-title":"Inhibitors of Bruton's tyrosine kinase reduce anti-red blood cell response in a murine model of autoimmune hemolytic anemia","volume":"128","author":"Rogers","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.tips.2024.06.006_bb0455","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood-2020-139131","article-title":"Effective treatment of cold agglutinin disease\/cold agglutinin syndrome with ibrutinib: an international case series","volume":"136","author":"Jalink","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.tips.2024.06.006_bb0460","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1474-4422(21)00250-7","article-title":"BTK inhibitors as potential therapies for multiple sclerosis","volume":"20","author":"Correale","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.tips.2024.06.006_bb0465","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S1474-4422(21)00237-4","article-title":"Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial","volume":"20","author":"Reich","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.tips.2024.06.006_bb0470","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/s41422-018-0055-1","article-title":"PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies","volume":"28","author":"Sun","year":"2018","journal-title":"Cell Res."},{"key":"10.1016\/j.tips.2024.06.006_bb0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2019.126877","article-title":"Design, synthesis and biological evaluation of proteolysis targeting chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties","volume":"30","author":"Jaime-Figueroa","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.tips.2024.06.006_bb0480","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2024.06.006_bb0485","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tips.2024.06.006_bb0490","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood.2021014162","article-title":"Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study","volume":"139","author":"Song","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.tips.2024.06.006_bb0495","doi-asserted-by":"crossref","first-page":"6801","DOI":"10.1182\/bloodadvances.2023010668","article-title":"Safety and efficacy of zanubrutinib in relapsed\/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study","volume":"7","author":"Opat","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.tips.2024.06.006_bb0500","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/ajh.26826","article-title":"Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma patients: multi-center, single-arm, open-label, phase 2 study","volume":"98","author":"Xu","year":"2023","journal-title":"Am. J. Hematol."}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614724001378?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614724001378?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T19:25:02Z","timestamp":1728501902000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614724001378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":100,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0165614724001378"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2024.06.006","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BTK inhibitors: past, present, and future","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2024.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}